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ABSTRACT 
The objective of the present study was to verify if severe physical health problems frequently 
encountered in heroin addicts and the concomitant use of alcohol and legal or illegal drugs other 
than heroin influenced the pharmacokinetics of the major metabolites of heroin. 
We conducted a 90 minutes follow-up of the plasma concentrations of the pharmaceutical 
heroin, named diacetylmorphine (DAM), in patients recruited in a DAM assisted treatment 
centre. TADAM (Traitement Assiste par DiAcetylMorphine) aimed to compare the efficacy of 
heroin-assisted treatment (HAT) compared with methadone maintenance treatment (MMT) for 
heroin users considered as treatment resistant patients and who have severe physical and 
mental health problems. 
Eleven patients were recruited. Blood samples were collected at baseline and 15, 45 and 90 
minutes after DAM administration. All patients received DAM bythe "chasing the dragon" route. 
Plasma samples were analyzed by a previously described ultra-high pressure liquid 
chromatography coupled to tandem mass spectrometry (UHPLC/MS-MS) method. 
A principal component analysis (PCA) was performed and 8 metabolite concentrations ratios 
were calculated to evaluate the influence of various factors (DAM dose, patient pathologies, 
concomitant use of medications, methadone, street heroin, alcohol and cocaine) on heroin 
metabolite pharmacokinetics. It seemed to be not affected by the DAM dose, patient pathologies 
and the concomitant use of medications, methadone, street heroin and alcohol. Cocaine use was 
the only parameter which showed differences in heroin pharmacokinetics. 
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In the European Union, between 1.3 and 1.4 million persons were considered as problematic 
opioid users in 2008 corresponding to 3.6-4.4 cases per 1000 population aged 15-64 years. (1). 
In Belgium, the use of heroin seemed to remain stable in 2005. The prevalence of heroin use was 
less than 1% but mortality varied from 5 to 35 per thousand person-years in opiate addicts (2). 
In order to reduce and possibly eliminate illicit heroin consumption and making patients more 
socially integrated, different substitution treatments were tried. Methadone maintenance 
treatment (MMT) is the first line treatment for opiate addicts in Belgium (1). However, among 
patients who followed MMT, many can be considered as treatment-resistant, sometimes because 
they don't respond positively to heroin replacement by methadone, sometimes because they 
present a genetic profile very different from others (3). It was suggested that for these patients, 
a treatment with pharmaceutical heroin could also be used as substitution treatment therapy 
(4). Since 1994, six countries experimented heroin-assisted treatment (HAT): Switzerland (4), 
the Netherlands (5), Spain (6), Germany (7), Canada (8) and the United Kingdom (9). It was 
shown that medical prescription of pharmaceutical heroin (diacetylmorphine or DAM) to 
chronic heroin addicts who have not responded favourably to MMT is effective in terms of 
physical and mental health, illicit heroin use and criminality and, in the same time, the feasibility 
and the safety of HAT were demonstrated (10-12). In Belgium, a project subsidized by the 
Federal Government, called TADAM (Traitement Assiste par DiAcetylMorphine), began in 
January 2011 in the city of Liege, where the number of heroin addicts is important (12). It is a 
randomised controlled study which evaluates the efficacy of MMT compared with HAT for 
patients who have been consuming heroin compulsively for many years, for whom MMT has 
failed and who present severe physical and mental health problems. When included, the patients 
received DAM prescribed by physicians one to three times a day in an outpatient centre where 
they can inject the product themselves or use the product by inhalation using the "chasing the 
dragon" technique: heroin is heated gently on aluminium foil with a lighter controlled by the 
patient. The heroin vapours generated by heating are inhaled into the lungs, using a straw in the 
mouth. The fumes appear to take the shape of the undulating tailof a dragon (13, 14). 
After penetration into the lungs, heroin is absorbed almost instantly. Heroin is considered as a 
pro-drug that acts mainly by its agonistic metabolites. In plasma, heroin is rapidly hydrolysed in 
6-monoacetylmorphine (6AM) and then into morphine. These reactions are catalysed by 
different types of esterases in blood (plasma and erythrocytes), liver and brain. Morphine is 
then glucuronidated by several subtypes of uridine-5'-diphosphateglucuronosyltransferase 
(UGT), mainly in the liver, resulting in morphine-3-glucuronide (M3G) and morphine-6-
glucuronide (M6G). The N-demethylation of morphine into the minor metabolite normorphine is 
mediated by cytochrome P450 enzymes 3A4 and 2C8 (11, 15). Heroin metabolism is presented 
in Figure 1. M3G has no affinity for the µ-opioid receptors and has no pharmacologic activity 
(15), but M6G remains psychoactive. 
Polydrug use including the combination of heroin with illicit drugs (cocaine and cannabis), 
alcohol and sometimes medicines (benzodiazepines, neuroleptics), is today very common 
among heroin addicts (1).Moreover, severe heroin addicts are often in poor health; they suffer 
from malnutrition (16) and the prevalence of hepatitis C and HIV infection is higher than in 
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general population because injecting drug users share contaminated injecting materials and 
have a high risk sexual behaviour (prostitution) (17, 18). The aim of the present study is to 
verify if the pharmacokinetics of the major metabolites of heroin is influenced by severe physical 
health problems (hepatitis C, HIV, nephropathy, etc) frequently encountered in a general 
population of heroin addicts and by concomitant use of alcohol and legal or illegal drugs other 
than heroin. To achieve this objective, we conducted a 90 minutes follow-up of the plasma 
concentrations of the DAM metabolites in patients recruited in the TADAM centre receiving DAM 
by the "chasing the dragon" route. No restrictions concerning health, concomitant medication, 
alcohol and cocaine use were defined. 
METHODS 
DIACETYLMORPHINE 
Diacetylmorphine was imported from the Netherlands, where injectable and inhalable forms of 
DAM were registered for opioid addiction treatment in 2006. The powder inhaled by the 
patients is a mix of heroin and caffeine in a ratio of 3: 1. 
PATIENTS 
Patient characteristics are presented in Table 1. Two female and nine male volunteers aged 29-
50 years were recruited for the study. Three patients (patients 1, 7 and 8) had a haemoglobin 
level lower than the lower limit of reference values. Four patients (patients 1, 2, 3 and 10) had 
impaired hepatic function with liver amino transferases ASAT (aspartate aminotransferase) and 
ALAT (alanine aminotransferase) and/or serum gamma-glutamyltransferase (GGT) higher than 
the normal upper limit. Three patients (patients 1, 2 and 4) had a disturbed renal function: they 
had a creatinine clearance lower than 90 ml/min. associated with a serum creatinine 
concentration of 179 µmol/L for patient 1, creatinine clearance was calculated according to the 
Cockcroft-Gault equation. 
Concerning comorbidity and comedications, patients 1 and 2 were HIV positive and received 
abacavir, lamivudine, lopinavir and ritonavir as antiretroviral treatment,4 patients were 
suffering from chronic hepatitis C; patients 1 and 3 were consuming high quantity of alcohol 
daily; 5 patients were receiving psychotropic drugs as chronic anxiety treatment; 3 received 30 
mg methadone daily. They were also using other psychotropic drugs: cocaine on a regular basis 
for 5 of them and cannabis for 8 of them. 
All patients received DAM 3 times a day (morning, midday and evening session) - except for 
patients 1 and 2 who received DAM 2 times a day (midday and evening session) - 7 days a week. 
DAM daily doses ranged between 600 and 900 mg. No dose changes had been made for a period 
of at least 15 days before entering the study. 
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Participation to the study was proposed to the patients on a voluntary basis and a written 
informed consent was obtained from all patients. The study protocol was approved by the Ethics 
Committee of the University of Liege (Belgian agreement n° B707201010144). 
The study took place during midday administration for 8 patients and during evening 
administration for 3 patients; the DAM dose ranged between 150 and 400 mg (median: 250 mg). 
DAM was self-administered (inhalation) under the supervision of trained nurses; the treatment 
duration was 20 minutes on average. Blood samples were drawn from an intravenous catheter 
placed in the arm at baseline (10 minutes before the treatment inhalation) and 15, 45 and 90 
minutes after the DAM administration. Between the first blood sampling and the last, the 
maximum delay was 2 hours. Patients had to stay in the TADAM deliverance centre all the time; 
they were allowed to smoke tobacco cigarettes twice. The sample at 90 minutes was not drawn 
for patient 1 because of venous sclerosis. 
SAMPLES ANALYSIS 
Blood was collected in two 4 ml polypropylene tubes, containing 2.25 mg/ml sodium fluoride. 
Sodium fluoride inhibits the plasma esterase activity and contributes to stabilise analyte 
concentration (19). Blood samples were centrifuged immediately and plasma fractions were 
stored at -20°C prior to analysis which was performed the following day. The quantification of 
opiates and opioids in plasma was done according to a previously described method (20). 
Briefly, 50 µL of deuterated internal standards were added to 500 µL of plasma which were next 
acidified with 0.15N HCI. Oasis MCX (30 mg, 1ml) cartridges purchased from Waters (Zellik, 
Belgium) were used for solid phase extraction (SPE). The conditioning was performed with 
methanol, water, and 1OmM citric acid and the acidified sample was loaded onto the column. 
Then, the cartridges were washed with 2% formic acid and dried. The elution was done with 
ammonia in methanol (5/95: VN). The eluate was evaporated to dryness and reconstituted with 
a mixture of 5 mM ammonium formate pH3 and methanol adjusted to pH3 with formic acid 
(90/lO:VN). Ten µL were injected on the ultra-high pressure liquid chromatograph (UHPLC) 
Acquity coupled to a tandem mass spectrometer Quattro Premier (Waters, Zellik, Belgium). The 
chromatographic separation was performed on an Acquity High Strength Silica HSS-T3 column 
(100x 2.1 mm, 1.8 µm, Waters). The mobile phase consisted in 5mM ammonium formate in 
water (pH3) and methanol adjusted to pH3 with formic acid delivered according to a gradient 
mode. The tandem mass spectrometer operated in the positive electrospray mode at 1.0 kV. Two 
multiple reaction monitoring (MRM) sequences were studied by analyte. Illicit heroin 
consumption markers (6-acetylcodeine, papaverine, noscapine, meconine and 7-
desmethylmeconine) were also analysed with this technique. 
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Figure 1. Heroin metabolism. 
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EXPLORATORY DATA ANALYSIS 
To understand the behaviour of the DAM metabolites and the correlation between various 
factors, a principal component analysis (PCA) on the correlation matrix was performed. The 
factors studied with the PCA where the logarithm of the concentrations of the DAM metabolites 
6AM, morphine, M3G, M6G, the dose of DAM administered and time of blood sampling. The first 
two principal components (PCs) explained 37.5% and 24.5% of the variability, respectively. 
Figure 2 shows the scores plot and the loadings plot of these two PCs. When looking at the 
scores plot in Figure 2, we can observe that these two PCs discriminate the patients in two 
groups: those who have consumed cocaine and those who have not. This group generation is 
mainly due to the 2nd PC and the loadings that are mostly responsible of this behaviour are 
morphine, M3G and M6G concentrations. 
Finally, the dose of DAM administered is strongly positively correlated with M3G and M6G 
concentrations and not correlated with 6AM concentration. 
PHARMACOKINETICS OF DAM METABOLITES 
The plasma concentrations-time curves of 6AM, morphine, M3G, M6G and normorphine are 
presented in Figure 3. 
Three patients (patients 1, 2 and 3) were found positive for 6AM in plasma samples collected 
prior to DAM administration. The highest concentration of 6AM was detected 15 minutes after 
the end of the inhalation, its median value was equal to 68 µg/L and ranged from 15 to 156 µg/L; 
the concentration decreased rapidly until 21 and 9 µg/L after 45 and 90 minutes respectively. 
The calculated 6AM plasma half-life was 22.6±9.2 minutes on average. 
Morphine was present in all collected samples. The residual median concentration of morphine 
at baseline was 68 µg/ L, ranging from 33 to 252 µg/L; morphine reached its highest level 15 
minutes after DAM administration with a median concentration of 158 µg/L. The morphine 
concentration decreased after 45 minutes for 8 patients. The morphine median concentrations 
were 138 and 117 µg/ L after 45 and 90 minutes respectively. The morphine plasma half-life 
was calculated at 140.6±67.8 minutes on average. 
M6G was found positive in all collected samples. The M6G plasma concentration at baseline was 
191 µg/L, ranging from 73 to 684 µg/L. The highest concentration of M6G was reached in 
samples taken at 45 and 90 minutes. The M6G median concentrations were 275,295 and 251 
µg/L after 15, 45 and 90 minutes respectively. 
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Figure 2. Scores plot and loadings plot of the two first principal components of the Principal Component 
Analysis of themetabolites 6AM (X6MAM), morphine, M3G, M6G, the dose of DAM administered (Dose) 
and the time of blood sampling (Time). 
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INFLUENCE OF BIOLOGICAL AND CLINICAL PARAMETERS ON DAM METABOLITE 
PHARMACOKINETICS 
The influence of biological andclinical parameters on DAM metabolite pharmacokinetics was 
evaluated on the basis of the study of 8 metabolite concentrations ratios calculated at each 
sampling time. The ratios between the different metabolites were chosen taking into account 
their chronology of appearance: DAM was first deacetylated in 6AM and in morphine which was 
then converted to M6G and M3G by glucuronidation. The 8 studied ratios are presented in Table 
3.It was shown that almost all ratios were stable during the 90 minutes followup except for 
ratios which have 6AM as denominator: "MOR/6AM '; "(MOR + M3G)/6AM'; "(MOR + 
M6G)/6AM" and "(MOR +M6G+M3G)/6AM''. 
Patients were grouped according to several criteria: low BMI (lower than 20), haemoglobin low 
level (lower than 13.3 g/dl), impaired renal function (creatinine clearance lower than 90 
ml/min.), disturbed hepatic function (GGT and/or ASAT and ALAT higher than the upper limit of 
normal), HIV and hepatitis C seropositivity, alcohol abuse, cocaine, methadone and psychotropic 
drug use. 
The mean values for the ratios and for 6AM and morphine half-lives were compared using a t-
student test and a Mann-Whitney test. 
For patients with hepatic disease (patients 1, 2, 3, 9 and 1O), when compared with other 
patients, no difference was found for the 8 tested ratios and for 6AM and morphine half-lives. 
Therefore, a disturbed hepatic function or chronic hepatitis C did not affect DAM 
pharmacokinetics. 
For patients suffering from impaired renal function (patients 1, 2 and 4), when compared with 
other patients, no difference was found between the 8 calculated ratios and between 6AM and 
morphine half-lives. Impairment of renal function did not significantly modify heroin 
transformation into metabolites. 
Similarly, low haemoglobin levels (patients 1,7 and 8) did not influence heroin metabolism since 
no difference between metabolite concentrations ratios and 6AM and morphine half-lives was 
observed. 
For the 2 patients (patients 1 and 2) infected by HIV and treated by abacavir, lamivudine, 
lopinavir and ritonavir, calculated ratios were not significantly different compared to 
seronegative patients. 
The same methodology was applied to patients consuming alcohol daily, patients treated with 
methadone and with psychotropic drugs showing that concomitant use of alcohol, methadone 
and psychotropic drugs did not change DAM metabolism. 
For the group of cocaine users, several differences were found for the calculated ratios as 
suggested previously by the scores plot of Figure 2. After 15 minutes, the ratios "MOR/6AM'; 
"(MOR + M3G)/6AM" and "(MOR + M6G)/6AM" were found respectively 2.0, 2.5 and 2.2 times 
lower in cocaine users compared to other patients. After 45 minutes, the 2 ratios "(MOR + 
M3G)/6AM" and "(MOR +M6G + M3G)/6AM" were found respectively 2.2 and 2.0 times lower 
in cocaine users. After 90 minutes, no ratio was found different in cocaine users. Mann-Whitney 
test for those ratios is presented in Table 4. 
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Finally, patient 2 was found positive for the markers of street heroin consumption 
(acetylcodeine, papaverine, noscapine, meconine and 7-desmethy lmeconine) but metabolite 
concentrations ratios were not modified. 
 
DISCUSSION 
The aim of the present study was to evaluate the evolution of heroin metabolite concentrations 
immediately after heroin consumption in severe heroin addicts without ineligibilities 
concerning health, comedication, alcohol and cocaine use. To our knowledge, only one study is 
available on heroin metabolite pharmacokinetics by the "chasing the dragon" technique in a 
general population of heroin addicts (21). Moreover, the pharmacokinetics of the "chasing the 
dragon" consumption mode has been investigated in only few studies (21, 22) while it is the 
most appreciated by occidental European heroin addicts since few years (1). Heroin metabolite 
concentrations levels were similar to levels found in other studies (21). The design of our study 
did not allow us to calculate the plasma half-life for M6G and M3G since their concentrations 
were not decreasing enough after 90 minutes which was the time of the last collected sample. 
6AM and morphine plasma half-lives were similar to those found inthe Rook's studies (21, 22). 
Almost all studied heroin metabolite concentrations ratios were stable - except for those which 
have 6AM as denominator - for all patients during the 90 minutes study whatever the DAM dose, 
the patient pathologies and the concomitant use of medications, methadone, street hemin and 
alcohol. Ratios with 6AM as denominator were found significantly lower in cocaine users and 
PCA showed two distinct groups depending on the consumption of cocaine. This can be 
explained by the fact that cocaine and heroin metabolism are catalysed by the same liver 
carboxylesterases (23); Rook et al. found that the terminal half-life of 6AM was prolonged by 
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13% in cocaine addicts (21).As shown on the scores plot of Figure 2, the cocaine users had 
generally higher blood concentration of 6AM and lower blood concentration of morphine, M3G 
and M6G than non-cocaine consumers. 
The ratio between psychoactive compounds (6AM, morphine, M6G) and the non-psychoactive 
metabolite (M3G) was stable; patients had therefore a constant quantity of circulating 
pharmacologically active substances during at least 4 hours, the elapsed time between morning 
and midday or between midday and evening administrations. 
The only metabolite concentrations ratio calculated in other studies was the M3G/M6G ratio 
which was equal to 7.0 on average in our study and was similar to the mean ratio of 5.8 found by 
E. Rook on 9 pharmaceutical heroin inhalers (21). It seems that antiretroviral therapy did not 
affect the pharmacokinetics of DAM, as it is the case for methadone (24), this could be expected 
since cytochrome P450 enzymes are not very involved in heroin metabolism. In the same order 
of ideas, we did not note influence of alcohol on heroin pharmacokinetics as it was suggested in 
another study (25). 
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The pharmacokinetics of heroin metabol ites seemed to be not affected by the DAM dose,patient 
pathologies and the concomitant use of medications, methadone, street heroin and alcohol. 
Cocaine use was the only parameter wich showed differences in heroin pharmacokinetics. 
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